Leukemia

Arsenic trioxide may be effective against resistant forms

Published in Blood Weekly, May 30th, 2002

by Michael Greer, senior medical writer - The antineoplastic agent arsenic trioxide (ATO) shows promise for the treatment of some drug-resistant forms of leukemia, researchers in France report.

"T-cell prolymphocytic leukemia (T-PLL) is a rare form of mature T-cell leukemia that is generally resistant to conventional chemotherapy," explained Dr. Christian Recher and colleagues at Saint Louis Hospital and Fernand Widal Hospital in Paris.

Animals suffering from this form of malignancy showed positive responses to ATO treatment, the researchers found.

Recher and coauthors studied mice engineered to carry the oncogene MTCP1,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2002-05-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry